{"filing":{"accession_number":"0001193125-26-271071","cik":"0001806952","ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"d102015d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/d102015d8k.htm"},"events":[{"id":11014,"run_id":9653,"accession_number":"0001193125-26-271071","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Lyell Immunopharma's June 10, 2026 annual meeting, covering three proposals: election of Class II directors (Richard Klausner, Otis Brawley, William Rieflin), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents certified voting tallies including votes for/against, withholdings, abstentions, and broker non-votes for each matter, which is the hallmark of Item 5.07 disclosure and directly matches the shareholder_vote_results event type.","company_name":"Lyell Immunopharma, Inc.","ticker":"LYEL","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7488,"accession_number":"0001193125-26-271071","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Lyell Immunopharma's June 10, 2026 annual meeting, covering three proposals: election of Class II directors (Richard Klausner, Otis Brawley, William Rieflin), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents certified voting tallies including votes for/against, withholdings, abstentions, and broker non-votes for each matter, which is the hallmark of Item 5.07 disclosure and directly matches the shareholder_vote_results event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:08:48.698212+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7488,"accession_number":"0001193125-26-271071","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Lyell Immunopharma's June 10, 2026 annual meeting, covering three proposals: election of Class II directors (Richard Klausner, Otis Brawley, William Rieflin), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents certified voting tallies including votes for/against, withholdings, abstentions, and broker non-votes for each matter, which is the hallmark of Item 5.07 disclosure and directly matches the shareholder_vote_results event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:08:48.698212+00:00","company_name":"Lyell Immunopharma, Inc.","ticker":"LYEL","filing_date":"2026-06-15"}]}